Akero Therapeutics (AKRO) News Today → [URGENT] DO NOT Touch These AI Stocks! (From Weiss Ratings) (Ad) Free AKRO Stock Alerts $19.92 -0.81 (-3.91%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 10:45 PM | prnewswire.comAKERO THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKROMay 17 at 3:58 AM | americanbankingnews.comShort Interest in Akero Therapeutics, Inc. (NASDAQ:AKRO) Rises By 5.1%May 17 at 2:44 AM | americanbankingnews.comAkero Therapeutics (NASDAQ:AKRO) Price Target Cut to $38.00May 16 at 6:50 PM | prnewswire.comAKRO Investors: Reminder - Important Deadline in Securities Fraud Class Action Lawsuit Akero Therapeutics, Inc.May 16 at 5:35 PM | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Akero Therapeutics, Inc. - AKROMay 16 at 4:45 PM | prnewswire.comAKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud LawsuitMay 16 at 2:42 AM | americanbankingnews.comAkero Therapeutics, Inc. Expected to Post FY2024 Earnings of ($3.86) Per Share (NASDAQ:AKRO)May 16 at 2:10 AM | americanbankingnews.comQ2 2024 EPS Estimates for Akero Therapeutics, Inc. Reduced by HC Wainwright (NASDAQ:AKRO)May 15 at 4:54 PM | marketbeat.comAkero Therapeutics (NASDAQ:AKRO) Shares Gap Up to $20.30Akero Therapeutics (NASDAQ:AKRO) Shares Gap Up to $20.30May 15 at 10:04 AM | marketbeat.comEvercore ISI Cuts Akero Therapeutics (NASDAQ:AKRO) Price Target to $38.00Evercore ISI dropped their price target on shares of Akero Therapeutics from $50.00 to $38.00 and set an "outperform" rating on the stock in a research note on Wednesday.May 15 at 8:41 AM | marketbeat.comAnalysts Offer Predictions for Akero Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:AKRO)Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) - Stock analysts at Lifesci Capital issued their FY2024 earnings estimates for shares of Akero Therapeutics in a research report issued to clients and investors on Monday, May 13th. Lifesci Capital analyst R. Katkhuda forecasts that the companyMay 15 at 7:49 AM | marketbeat.comAkero Therapeutics, Inc. to Post Q2 2024 Earnings of ($0.82) Per Share, HC Wainwright Forecasts (NASDAQ:AKRO)Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) - HC Wainwright dropped their Q2 2024 EPS estimates for Akero Therapeutics in a report released on Monday, May 13th. HC Wainwright analyst E. Arce now forecasts that the company will earn ($0.82) per share for the quarter, down from their priorMay 15 at 4:50 AM | americanbankingnews.comAkero Therapeutics (NASDAQ:AKRO) PT Lowered to $56.00 at Canaccord Genuity GroupMay 15 at 4:10 AM | americanbankingnews.comAkero Therapeutics (NASDAQ:AKRO) Receives Buy Rating from HC WainwrightMay 15 at 3:24 AM | americanbankingnews.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Given Average Rating of "Moderate Buy" by AnalystsMay 15 at 3:24 AM | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Receives Average Rating of "Moderate Buy" from AnalystsShares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eight brokerages that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and seven have assigneMay 15 at 1:40 AM | americanbankingnews.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Expected to Post Q2 2024 Earnings of ($0.95) Per ShareMay 14 at 5:08 PM | prnewswire.comROSEN, SKILLED INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKROMay 14 at 4:57 PM | markets.businessinsider.comSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero TherapeuticsMay 14 at 8:08 AM | marketbeat.comQ2 2024 Earnings Estimate for Akero Therapeutics, Inc. (NASDAQ:AKRO) Issued By Lifesci CapitalAkero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) - Stock analysts at Lifesci Capital issued their Q2 2024 earnings estimates for shares of Akero Therapeutics in a note issued to investors on Monday, May 13th. Lifesci Capital analyst R. Katkhuda anticipates that the company will post earningsMay 13, 2024 | businesswire.comKirby McInerney LLP Reminds Akero Therapeutics, Inc. (AKRO) Investors of Class Action Filing and Encourages Investors to Contact the FirmMay 13, 2024 | markets.businessinsider.comPositive Buy Rating for Akero Therapeutics Backed by Clinical and Operational ProgressMay 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL), Akero Therapeutics (AKRO) and Madrigal Pharmaceuticals (MDGL)May 13, 2024 | marketbeat.comAkero Therapeutics (NASDAQ:AKRO) PT Lowered to $56.00Canaccord Genuity Group dropped their target price on Akero Therapeutics from $59.00 to $56.00 and set a "buy" rating on the stock in a research report on Monday.May 13, 2024 | marketbeat.comAkero Therapeutics (NASDAQ:AKRO) Receives "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $50.00 target price on shares of Akero Therapeutics in a research note on Monday.May 13, 2024 | finance.yahoo.comAkero Therapeutics Inc (AKRO) Q1 2024 Earnings: Misses Analyst Forecast Amid Continued ...May 12, 2024 | markets.businessinsider.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero TherapeuticsMay 10, 2024 | prnewswire.comAKERO THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKROMay 10, 2024 | businesswire.comAKRO Stockholders with Large Losses Should Contact Robbins LLP for Information About the Class Action Against Akero Therapeutics, Inc.May 10, 2024 | prnewswire.comAKRO Investors: Reminder - Important Deadline in Securities Fraud Class Action Lawsuit Akero Therapeutics, Inc.May 10, 2024 | investorplace.comAKRO Stock Earnings: Akero Therapeutics Beats EPS for Q1 2024May 10, 2024 | businesswire.comGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akero Therapeutics, Inc. (AKRO)May 10, 2024 | markets.businessinsider.comAkero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 10, 2024 | msn.comAkero Therapeutics GAAP EPS of -$0.90 beats by $0.05May 10, 2024 | globenewswire.comAkero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 8, 2024 | globenewswire.comAkero Therapeutics to Present at the BofA Securities 2024 Health Care ConferenceMay 8, 2024 | prnewswire.comAKRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!May 7, 2024 | stockhouse.comAkero Therapeutics (AKRO) Slides After Failed Trial, Hit With Class Action Lawsuit - Hagens BermanMay 7, 2024 | prnewswire.comROSEN, GLOBAL INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKROMay 7, 2024 | prnewswire.comClass Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Akero Therapeutics, Inc.May 7, 2024 | businesswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Akero Therapeutics, Inc. (AKRO) InvestorsMay 6, 2024 | stockhouse.comThe Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Akero Therapeutics, Inc. (AKRO) InvestorsMay 6, 2024 | markets.businessinsider.comINVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the FirmMay 6, 2024 | marketbeat.comAkero Therapeutics (NASDAQ:AKRO) Trading 5.5% Higher Akero Therapeutics (NASDAQ:AKRO) Trading Up 5.5%May 6, 2024 | businesswire.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Akero Therapeutics, Inc. (AKRO) InvestorsMay 5, 2024 | markets.businessinsider.comONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero TherapeuticsMay 5, 2024 | stockhouse.comAKRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Akero Therapeutics, Inc. Investors Can Join the Class Action Lawsuit!May 3, 2024 | prnewswire.comAKERO THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKROMay 3, 2024 | markets.businessinsider.comINVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the FirmMay 3, 2024 | businesswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Akero Therapeutics, Inc. (AKRO) on Behalf of Investors Get Akero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon’s New Device is About to Shock the World (Ad)Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. AKRO Media Mentions By Week AKRO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AKRO News Sentiment▼0.300.54▲Average Medical News Sentiment AKRO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AKRO Articles This Week▼425▲AKRO Articles Average Week Get Akero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ANI Pharmaceuticals News Morphic News Kiniksa Pharmaceuticals News Gemini Therapeutics News Pacira BioSciences News Dynavax Technologies News Day One Biopharmaceuticals News Avadel Pharmaceuticals News Gyre Therapeutics News Ligand Pharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AKRO) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressThe Next Industry Being Reshaped By AIThe Bull ReportWhy Is Gold On a MASSIVE rally? Huge AlertsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingElon’s New Device is About to Shock the WorldInvestorPlaceUrgent Nvidia WarningAltimetryMissed NVDA? Buy this AI stock NOWChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
